Elucid
PrivateLast Round
Series D
Sep 2, 2026
Total Funding Raised
$170.75M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Elucid operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series D round in September 2026.
Elucid is a medical technology company that develops AI-powered imaging software to quantify and characterize atherosclerotic plaque for personalized cardiovascular disease treatment.
Sector
Healthcare & Life Sciences
Verticals
Medical Imaging, Medical AI, Medical Devices, Healthcare Analytics, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Elucid Comparables
Compare Elucid with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cleerly | 91% | |
| Artrya Ltd | 83% | |
| Circle Cardiovascular Imaging | 83% |
For institutional investors. Book with your work email.
Elucid Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 2, 2026 | ||||
| Series C | Nov 9, 2023 | ||||
| Series B | Jun 22, 2022 | ||||
| Series A | May 10, 2021 | ||||
| Grant | Sep 1, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Elucid Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bold Brain | Series B |
| IAG Capital Partners | Series B, Series A, Series D |
| MedTex Ventures | Series B, Series C, Series A |
| NIH RADx | Grant |
| Bioverge | Series B |
| Willamette Valley Capital | Series A |
| Checkmate Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 2, 2026
$55M round with IAG Capital Partners and Elevage Medical Technologies.
- Apr 15, 2026
Commercial availability of the Lesion Inspection Tool for plaque analysis.
For institutional investors. Book with your work email.
Elucid Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Elucid's valuation, stock price, and market status.
Is Elucid a public or private company?
Elucid is a private company.
What is the current stock price of Elucid?
Elucid is a private company, so its shares have no public market price. Caplight tracks Elucid's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Elucid worth (valuation)?
Valuation information for Elucid is not publicly available.
Can I buy Elucid stock?
Elucid shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Elucid's last funding round?
Elucid's most recent funding round was Series D on September 2, 2026.
Who are the main investors in Elucid?
Key investors in Elucid include MedTex Ventures, Elevage Medical Technologies.
Will Elucid IPO soon?
No public IPO plans have been announced for Elucid.
How can I track Elucid secondary market activity?
Caplight tracks bids, offers, and trades in Elucid's shares on secondary markets.